NCT00135863

MesoHep II: Intraperitoneal Low Molecular Weight Heparin in Peritoneal Dialysis

Intraperitoneal Low Molecular Weight Heparin in Peritoneal Dialysis

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 36 (planned)
• Sponsor: Ribe County Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Patients with end stage renal disease (ESRD) who use peritoneal dialyses with Physioneal(R) (Baxter A/S, Denmark) were allocated to inject either placebo or tinzaparin daily into the morning dialysis bag. Active medication, as well as placebo, was added for three months separated by a one month washout period. At the beginning and end of each treatment period peritoneal equilibrations tests (PE-tests), Kt/V, blood and dialysate samples were analyzed. We, the researchers at Ribe County Hospital, set out to examine inflammation (local and systemic), nutrition and ultrafiltration.

Conditions

• Inflammation
• Nutrition
• Peritoneal Dialysis

Interventions

Type	Name	Description
DRUG	tinzaparin

Timeline

• Start date: 2004-05-01
• Completion: 2005-05-01
• First posted: 2005-08-26
• Last updated: 2015-05-21

Locations

1 site across 1 country: Denmark